FDA Needs More Data on Tebipenem HBr for Complicated UTI
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Spero Therapeutics regarding the New Drug Application (NDA) for tebipenem HBr (tebipenem pivoxil hydrobromide) for the treatment of adults with complicated…